Regulus Therapeutics Given Average Recommendation of “Buy” by Analysts (NASDAQ:RGLS)
Shares of Regulus Therapeutics (NASDAQ:RGLS) have been given an average rating of “Buy” by the nine ratings firms that are currently covering the stock, AmericanBankingNews.com reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $16.20.
Regulus Therapeutics (NASDAQ:RGLS) traded up 0.60% on Friday, hitting $6.76. The stock had a trading volume of 7,238 shares. Regulus Therapeutics has a 52 week low of $5.40 and a 52 week high of $11.88. The stock has a 50-day moving average of $7.12 and a 200-day moving average of $7.99. The company’s market cap is $293.1 million.
Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.10. On average, analysts predict that Regulus Therapeutics will post $-0.89 earnings per share for the current fiscal year.
RGLS has been the subject of a number of recent research reports. Analysts at FBR Capital Markets raised their price target on shares of Regulus Therapeutics from $14.00 to $15.00 in a research note on Thursday. They now have an “outperform” rating on the stock. Analysts at Brinson Patrick initiated coverage on shares of Regulus Therapeutics in a research note on Tuesday, May 13th. They set an “outperform” rating on the stock.
Regulus Therapeutics Inc, is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.